Bellerophon Therapeutics Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Craig Jalbert
Chief executive officer
n/a
Total compensation
CEO salary percentage | n/a |
CEO tenure | less than a year |
CEO ownership | n/a |
Management average tenure | no data |
Board average tenure | no data |
Recent management updates
Recent updates
Bellerophon Therapeutics (NASDAQ:BLPH) Will Have To Spend Its Cash Wisely
Jan 06Bellerophon stock gains ~24% after getting FDA nod to reduce phase 3 study size
Sep 27Bellerophon Therapeutics GAAP EPS of -$0.43 beats by $0.17
Aug 15Is Bellerophon Therapeutics (NASDAQ:BLPH) In A Good Position To Invest In Growth?
Jan 18Bellerophon Therapeutics EPS misses by $0.01
Nov 05CEO
Craig Jalbert (61 yo)
less than a year
Tenure
Mr. Craig R. Jalbert, CIRA, serves as President, Corporate Secretary, Principal Executive Officer, Principal Financial Officer and Principal Accounting Officer at Evelo Biosciences, Inc. since November 21,...